Arcus Biosciences, Inc. (RCUS) financial statements and ratios from SEC XBRL: revenue $0.2B (TTM), net margin -142.9%, revenue growth -4.3% YoY. Income statement, balance sheet, cash flow, and valuation. First-party data.
| Revenue (latest FY) | $247.00M |
| Revenue (TTM) | $0.2B |
| Net Margin | -142.9% |
| Operating Margin (TTM) | -168.6% |
| Net Debt / EBITDA | 0.3 |
| Revenue Growth (YoY) | -4.3% |
| EPS Growth (YoY) | 4.8% |
| FCF Growth (YoY) | 175.0% |
| Price / Book | 7.29 |
| Price / Sales | 16.54 |
| FCF Yield | -23.6% |
| Altman Z-Score | 2.59 (grey) |
| Industry P/E (Pharmaceutical Products) | 17.2 |
| Sector P/E (Healthcare) | 21.7 |
RCUS overview · RCUS earnings · RCUS KPIs · RCUS documents · RCUS ownership · RCUS peers
Data sourced from U.S. SEC EDGAR XBRL filings. Not personalized investment advice.